Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH

Am J Kidney Dis. 2016 Mar;67(3):532-3. doi: 10.1053/j.ajkd.2015.11.009. Epub 2015 Dec 23.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Atypical Hemolytic Uremic Syndrome* / drug therapy
  • Atypical Hemolytic Uremic Syndrome* / genetics
  • Atypical Hemolytic Uremic Syndrome* / physiopathology
  • Complement Factor H / genetics*
  • Humans
  • Immunologic Factors / administration & dosage
  • Mutation
  • Pharmacogenetics / methods
  • Precision Medicine
  • Secondary Prevention
  • Withholding Treatment

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors
  • Complement Factor H
  • eculizumab